ATE414539T1 - Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen - Google Patents

Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen

Info

Publication number
ATE414539T1
ATE414539T1 AT03734121T AT03734121T ATE414539T1 AT E414539 T1 ATE414539 T1 AT E414539T1 AT 03734121 T AT03734121 T AT 03734121T AT 03734121 T AT03734121 T AT 03734121T AT E414539 T1 ATE414539 T1 AT E414539T1
Authority
AT
Austria
Prior art keywords
methods
kallikrein
inflammatory conditions
diagnosis
treatment
Prior art date
Application number
AT03734121T
Other languages
English (en)
Inventor
Isobel Scarisbrick
Sachiko Blaber
Michael Blaber
Original Assignee
Mayo Foundation
Univ Florida State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation, Univ Florida State filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE414539T1 publication Critical patent/ATE414539T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
AT03734121T 2002-05-21 2003-05-21 Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen ATE414539T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38247102P 2002-05-21 2002-05-21

Publications (1)

Publication Number Publication Date
ATE414539T1 true ATE414539T1 (de) 2008-12-15

Family

ID=29584413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03734121T ATE414539T1 (de) 2002-05-21 2003-05-21 Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen

Country Status (8)

Country Link
US (3) US7754216B2 (de)
EP (2) EP2189166A1 (de)
AT (1) ATE414539T1 (de)
AU (1) AU2003239558A1 (de)
CA (1) CA2486619A1 (de)
DE (1) DE60324796D1 (de)
ES (1) ES2316770T3 (de)
WO (1) WO2003099328A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4135019B2 (ja) * 2006-04-28 2008-08-20 住友電気工業株式会社 半導体レーザ
US8530427B2 (en) * 2010-09-30 2013-09-10 Mayo Foundation For Medical Education And Research Methods for modulating resistance to apoptosis using KLK6
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
US9783587B1 (en) 2014-05-09 2017-10-10 Florida State University Research Foundation Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins
US20160213633A1 (en) * 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5750666A (en) 1988-05-26 1998-05-12 Competitve Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5296347A (en) 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AU4480797A (en) * 1996-09-13 1998-04-02 Dana-Farber Cancer Institute Protease m, a novel serine protease
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
AU755340B2 (en) * 1998-07-02 2002-12-12 Fuso Pharmaceutical Industries, Ltd. Serine protease-specific monoclonal antibody and utilization thereof
CA2360219A1 (en) * 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease

Also Published As

Publication number Publication date
EP2189166A1 (de) 2010-05-26
WO2003099328A1 (en) 2003-12-04
CA2486619A1 (en) 2003-12-04
DE60324796D1 (de) 2009-01-02
US20060127391A1 (en) 2006-06-15
EP1513553B1 (de) 2008-11-19
EP1513553A1 (de) 2005-03-16
US20130323262A1 (en) 2013-12-05
EP1513553A4 (de) 2006-03-22
AU2003239558A1 (en) 2003-12-12
US7754216B2 (en) 2010-07-13
US20110008789A1 (en) 2011-01-13
ES2316770T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
ATE516042T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
DE60331892D1 (de) Operationsinstrument und Verfahren zur Behandlung von Organvorfall
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE515268T1 (de) Verwendung von op-1 zur behandlung von knorpeldefekten
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60120667D1 (de) Methoden und mittel zur behandlung von bandscheibenverschleiss
DE60043075D1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE60127986D1 (de) Bildgebende verfahren, diagnose und behandlung von krankheiten
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE60335636D1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE521631T1 (de) Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
ATE414539T1 (de) Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE362362T1 (de) Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties